Literature DB >> 24947991

Medical, psychological and social features in a large cohort of adults with Prader-Willi syndrome: experience from a dedicated centre in France.

V Laurier1, A Lapeyrade, P Copet, G Demeer, M Silvie, E Bieth, M Coupaye, C Poitou, F Lorenzini, F Labrousse, C Molinas, M Tauber, D Thuilleaux, J Jauregi.   

Abstract

BACKGROUND: Prader-Willi syndrome (PWS) is a developmental genetic disorder characterised by a variable expression of medical, cognitive and behavioural symptoms. In adulthood, the prevalence and severity of these symptoms determine the quality of life of the affected persons. Because of their rare disease condition, data on health and social problems in adults with PWS are scarce. In this research, we present medical, psychological and social features of a large cohort of adults admitted to a specialised PWS centre in France and analyse the differences according to genotype, gender and age.
METHODS: Data from 154 patients (68 men/86 women), with a median age of 27 years (range 16-54), were collected during their stay in our centre. Clinical histories were completed using information from parents or main caregivers, and the same medical team performed the diagnosis of different clinical conditions. Statistical analyses were performed to determine the influence of factors such as genotype, age or gender.
RESULTS: Paternal deletion genotype was the most frequent (65%) at all ages. Most patients had mild or moderate intellectual disability (87%). Only 30% had studied beyond primary school and 70% were in some special educational or working programme. Most of them lived in the family home (57%). The most prevalent somatic comorbidities were scoliosis (78%), respiratory problems (75%), dermatological lesions (50%), hyperlipidaemia (35%), hypothyroidism (26%), Type 2 diabetes mellitus (25%) and lymph oedema (22%). Some form of psychotropic treatment was prescribed in 58% of subjects, and sex hormones in 43%. Patients with deletion had a higher body mass index (44 vs. 38.9 kg/m(2)) and displayed higher frequency of sleep apnoeas. Non-deletion patients received insulin treatment (19% vs. 4%) and antipsychotic treatment (54.8% vs. 32.7%) more frequently. No difference was observed in the prevalence of Type 2 diabetes between the two genotype groups. Patients >27 years of age had a higher rate of comorbidities (Type 2 diabetes, hypertension, respiratory problems and lymph oedema). Gender differences were minor.
CONCLUSIONS: Adult patients with PWS showed high prevalence of comorbid health problems that need to be monitored for early treatment. Some of them are influenced by genotype and age. Another salient problem concerns the lack of adapted structures for better social integration. Further data about the real life and health conditions of adults with PWS are necessary to further our knowledge of the natural history of the disease and to design appropriate care strategies.
© 2014 MENCAP and International Association of the Scientific Study of Intellectual and Developmental Disabilities and John Wiley & Sons Ltd.

Entities:  

Keywords:  Prader-Willi syndrome; cognitive behaviour; genotype; intellectual disability

Mesh:

Year:  2014        PMID: 24947991     DOI: 10.1111/jir.12140

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  19 in total

1.  Contributing factors of mortality in Prader-Willi syndrome.

Authors:  Jennifer Proffitt; Kathryn Osann; Barbara McManus; Virginia E Kimonis; Janalee Heinemann; Merlin G Butler; David A Stevenson; June-Anne Gold
Journal:  Am J Med Genet A       Date:  2018-12-19       Impact factor: 2.802

Review 2.  Update on Diabetes Mellitus and Glucose Metabolism Alterations in Prader-Willi Syndrome.

Authors:  Antonino Crinò; Graziano Grugni
Journal:  Curr Diab Rep       Date:  2020-02-06       Impact factor: 4.810

3.  Associations Between Hyperphagia, Symptoms of Sleep Breathing Disorder, Behaviour Difficulties and Caregiver Well-Being in Prader-Willi Syndrome: A Preliminary Study.

Authors:  Jessica Mackay; Gillian M Nixon; Antony R Lafferty; Geoff Ambler; Nitin Kapur; Philip B Bergman; Cara Schofield; Chris Seton; Andrew Tai; Elaine Tham; Komal Vora; Patricia Crock; Charles Verge; Yassmin Musthaffa; Greg Blecher; Daan Caudri; Helen Leonard; Peter Jacoby; Andrew Wilson; Catherine S Choong; Jenny Downs
Journal:  J Autism Dev Disord       Date:  2021-09-08

4.  Endocrine and Metabolic Illnesses in Young Adults with Prader-Willi Syndrome.

Authors:  Eu-Seon Noh; Min-Sun Kim; Chiwoo Kim; Kyeongman Jeon; Seonwoo Kim; Sung Yoon Cho; Dong-Kyu Jin
Journal:  J Pers Med       Date:  2022-05-25

5.  Patterns of Risk for Multiple Co-Occurring Medical Conditions Replicate Across Distinct Cohorts of Children with Autism Spectrum Disorder.

Authors:  Kimberly A Aldinger; Christianne J Lane; Jeremy Veenstra-VanderWeele; Pat Levitt
Journal:  Autism Res       Date:  2015-05-24       Impact factor: 5.216

6.  AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.

Authors:  Soraya Allas; Assumpta Caixàs; Christine Poitou; Muriel Coupaye; Denise Thuilleaux; Françoise Lorenzini; Gwenaëlle Diene; Antonino Crinò; Frédéric Illouz; Graziano Grugni; Diane Potvin; Sarah Bocchini; Thomas Delale; Thierry Abribat; Maithé Tauber
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

Review 7.  Medication Trials for Hyperphagia and Food-Related Behaviors in Prader-Willi Syndrome.

Authors:  Jennifer L Miller; Theresa V Strong; Janalee Heinemann
Journal:  Diseases       Date:  2015-06-03

8.  Is ghrelin a biomarker of early-onset scoliosis in children with Prader-Willi syndrome?

Authors:  Dibia Liz Pacoricona Alfaro; Gwenaelle Diene; Graziella Pinto; Jean-Pierre Salles; Isabelle Gennero; Sandy Faye; Catherine Molinas; Marion Valette; Catherine Arnaud; Maithé Tauber
Journal:  Orphanet J Rare Dis       Date:  2021-07-08       Impact factor: 4.123

9.  Paradoxical low severity of COVID-19 in Prader-Willi syndrome: data from a French survey on 647 patients.

Authors:  Muriel Coupaye; Virginie Laurier; Grégoire Benvegnu; Christine Poitou; Pauline Faucher; Héléna Mosbah; Gwenaelle Diene; Graziella Pinto; Laura González Briceño; Christine Merrien; Ana Camarena Toyos; Emilie Montastier; Maithé Tauber; Fabien Mourre
Journal:  Orphanet J Rare Dis       Date:  2021-07-21       Impact factor: 4.123

Review 10.  Hypothalamic neuropeptides and neurocircuitries in Prader Willi syndrome.

Authors:  Felipe Correa-da-Silva; Eric Fliers; Dick F Swaab; Chun-Xia Yi
Journal:  J Neuroendocrinol       Date:  2021-06-22       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.